Stoke Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of operations and comprehensive income (loss)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	$13,817	$4,831	$172,386	$9,048
Operating expenses:
Research and development	25,855	21,136	58,531	43,504
General and administrative	15,262	13,037	29,915	23,258
Total operating expenses	41,117	34,173	88,446	66,762
Income (loss) from operations	(27,300)	(29,342)	83,940	(57,714)
Other income (expense):
Interest income (expense), net	3,789	3,695	6,678	6,121
Other income (expense), net	28	(48)	57	(476)
Total other income (expense)	3,817	3,647	6,735	5,645
Income (loss) before income taxes	$(23,483)	$(25,695)	$90,675	$(52,069)
Provision for income taxes	—	—	1,278	—
Net income (loss)	$(23,483)	$(25,695)	$89,397	$(52,069)
Net income (loss) per share:
Basic	$(0.40)	$(0.46)	$1.54	$(1.02)
Diluted	(0.40)	(0.46)	$1.50	(1.02)
Weighted-average common shares outstanding:
Basic	58,353,855	55,765,948	$58,109,622	51,288,222
Diluted	58,353,855	55,765,948	$59,681,472	51,288,222
Comprehensive income (loss):
Net income (loss)	$(23,483)	$(25,695)	$89,397	$(52,069)
Other comprehensive gain (loss):
Unrealized gain (loss) on marketable securities	200	(15)	247	9
Total other comprehensive gain (loss)	$200	$(15)	$247	$9
Comprehensive income (loss)	$(23,283)	$(25,710)	$89,644	$(52,060)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.